Spadafora Marco, Sannino Pasqualina, Mansi Luigi, Mainolfi Ciro, Capasso Rosario, Di Giorgio Eugenio, Fiordoro Salvatore, Imbimbo Serena, Masone Filomena, Evangelista Laura
Nuclear Medicine Unit, Ospedale del Mare, Naples, Italy.
CIRPS, Interuniversity Research Center for Sustainability, Rome, Italy.
Nucl Med Mol Imaging. 2023 Jun;57(3):137-144. doi: 10.1007/s13139-023-00788-4. Epub 2023 Feb 4.
This study is to use a simple algorithm based on patient's age to reduce the overall biological detriment associated with PET/CT.
A total of 421 consecutive patients (mean age 64 ± 14 years) undergoing PET for various clinical indications were enrolled. For each scan, effective dose (ED in mSv) and additional cancer risk (ACR) were computed both in a reference condition (REF) and after applying an original algorithm (ALGO). The ALGO modified the mean dose of FDG and the PET scan time parameters; indeed, a lower dose and a longer scan time were reported in the younger, while a higher dose and a shorter scan time in the older patients. Moreover, patients were classified by age bracket (18-29, 30-60, and 61-90 years).
The ED was 4.57 ± 0.92 mSv in the REF condition. The ACR were 0.020 ± 0.016 and 0.0187 ± 0.013, respectively, in REF and ALGO. The ACR for the REF and ALGO conditions were significantly reduced in males and females, although it was more evident in the latter gender (all < 0.0001). Finally, the ACR significantly reduced from the REF condition to ALGO in all three age brackets (all < 0.0001).
Implementation of ALGO protocols in PET can reduce the overall ACR, mainly in young and female patients.
本研究旨在使用一种基于患者年龄的简单算法，以降低与PET/CT相关的总体生物损害。
共纳入421例因各种临床指征接受PET检查的连续患者（平均年龄64±14岁）。对于每次扫描，在参考条件（REF）下以及应用原始算法（ALGO）后，计算有效剂量（以mSv为单位的ED）和额外癌症风险（ACR）。ALGO修改了FDG的平均剂量和PET扫描时间参数；实际上，年轻患者的剂量较低且扫描时间较长，而老年患者的剂量较高且扫描时间较短。此外，患者按年龄组（18 - 29岁、30 - 60岁和61 - 90岁）进行分类。
在REF条件下，ED为4.57±0.92 mSv。REF和ALGO中的ACR分别为0.020±0.016和0.0187±0.013。REF和ALGO条件下的ACR在男性和女性中均显著降低，尽管在女性中更为明显（均<0.0001）。最后，在所有三个年龄组中，ACR从REF条件到ALGO均显著降低（均<0.0001）。
在PET中实施ALGO方案可降低总体ACR，主要是在年轻和女性患者中。
